Target Price | $506.62 |
Price | $282.28 |
Potential | 79.47% |
Number of Estimates | 13 |
13 Analysts have issued a price target MicroStrategy 2026 . The average MicroStrategy target price is $506.62. This is 79.47% higher than the current stock price. The highest price target is $650.00 130.27% , the lowest is $220.00 22.06% . | |
A rating was issued by 15 analysts: 14 Analysts recommend MicroStrategy to buy, 0 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the MicroStrategy stock has an average upside potential 2026 of 79.47% . Most analysts recommend the MicroStrategy stock at Purchase. |
12 Analysts have issued a sales forecast MicroStrategy 2025 . The average MicroStrategy sales estimate is $474m . This is 2.32% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $501m 8.14% , the lowest is $456m 1.65% .
This results in the following potential growth metrics:
2024 | $463m | 6.61% |
---|---|---|
2025 | $474m | 2.32% |
2026 | $492m | 3.79% |
2027 | $492m | 0.04% |
2028 | $454m | 7.79% |
2029 | $476m | 5.00% |
5 Analysts have issued an MicroStrategy EBITDA forecast 2025. The average MicroStrategy EBITDA estimate is $48.3m . This is 231.05% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $68.6m 286.26% , the lowest is $35.1m 195.38% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $-24.5m | 176.49% |
---|---|---|
2025 | $48.3m | 296.76% |
2026 | $70.2m | 45.44% |
2024 | -5.29% | 181.90% |
---|---|---|
2025 | 10.18% | 292.34% |
2026 | 14.26% | 40.08% |
7 MicroStrategy Analysts have issued a net profit forecast 2025. The average MicroStrategy net profit estimate is $-94.8m . This is 93.15% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $-46.7m 96.63% , the lowest is $-128m 90.76% .
This results in the following potential growth metrics and future Net Margins:
2024 | $-1.5b | 329.55% |
---|---|---|
2025 | $-94.8m | 93.64% |
2026 | $-101m | 6.81% |
2027 | $-157m | 55.34% |
2028 | $74.9b | 47,707.16% |
2029 | $123b | 63.64% |
2024 | -321.37% | 345.79% |
---|---|---|
2025 | -19.99% | 93.78% |
2026 | -20.57% | 2.90% |
2027 | -31.97% | 55.42% |
2028 | 16,505.49% | 51,728.06% |
2029 | 25,722.67% | 55.84% |
7 Analysts have issued a MicroStrategy forecast for earnings per share. The average MicroStrategy EPS is $-0.39 . This is 93.07% higher than earnings per share in the financial year 2024. The highest EPS forecast is $-0.19 96.63% , the lowest is $-0.52 90.76% .
This results in the following potential growth metrics and future valuations:
2024 | $-6.06 | 329.55% |
---|---|---|
2025 | $-0.39 | 93.56% |
2026 | $-0.41 | 5.13% |
2027 | $-0.64 | 56.10% |
2028 | $304.69 | 47,707.81% |
2029 | $498.58 | 63.64% |
Current | -50.10 | 182.84% |
---|---|---|
2025 | -731.84 | 1,360.76% |
2026 | -685.15 | 6.38% |
2027 | -441.06 | 35.63% |
2028 | 0.93 | 100.21% |
2029 | 0.57 | 38.71% |
Based on analysts' sales estimates for 2025, the MicroStrategy stock is valued at an EV/Sales of 170.26 and an P/S ratio of 155.04 .
This results in the following potential growth metrics and future valuations:
Current | 174.21 | 177.71% |
---|---|---|
2025 | 170.26 | 2.27% |
2026 | 164.04 | 3.65% |
2027 | 164.10 | 0.04% |
2028 | 177.96 | 8.45% |
2029 | 169.48 | 4.76% |
Current | 158.64 | 172.19% |
---|---|---|
2025 | 155.04 | 2.27% |
2026 | 149.37 | 3.65% |
2027 | 149.43 | 0.04% |
2028 | 162.05 | 8.45% |
2029 | 154.33 | 4.76% |
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Overweight
➜
Overweight
|
Unchanged | Feb 10 2025 |
Keefe, Bruyette & Woods |
➜
Outperform
|
Initiated | Feb 07 2025 |
Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Feb 06 2025 |
Maxim Group |
Buy
➜
Buy
|
Unchanged | Feb 06 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Feb 06 2025 |
Mizuho |
➜
Outperform
|
Initiated | Jan 29 2025 |
Benchmark |
Buy
➜
Buy
|
Unchanged | Jan 14 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Feb 10 2025 |
Initiated
Keefe, Bruyette & Woods:
➜
Outperform
|
Feb 07 2025 |
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Feb 06 2025 |
Unchanged
Maxim Group:
Buy
➜
Buy
|
Feb 06 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Feb 06 2025 |
Initiated
Mizuho:
➜
Outperform
|
Jan 29 2025 |
Unchanged
Benchmark:
Buy
➜
Buy
|
Jan 14 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.